Literature DB >> 17559990

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

Robert L Atmar1, Wendy A Keitel, Thomas R Cate, Flor M Munoz, Fred Ruben, Robert B Couch.   

Abstract

Epidemic influenza occurs annually throughout the world and is accompanied by excess morbidity and mortality. Increasing the antigen content and topical administration of vaccine are two strategies being explored to improve the immune responses to trivalent inactivated influenza vaccine (TIV). We conducted a randomized, double-blind, placebo-controlled trial to compare the immunogenicity and reactogenicity of intramuscular (IM), intranasal (IN), or combined IM and IN administration of a contemporary US vaccine formulation at escalating dosage levels in young healthy adults. Two hundred forty three healthy adults between the ages of 18 and 45 years received 15, 30, or 60mcg of trivalent inactivated influenza vaccine by either IN, IM or both routes, 120mcg of vaccine IM, or placebo IN and IM. All dosages and routes of vaccine administration were well-tolerated. A bad taste and mild nasal discomfort were more likely to be reported when influenza vaccine was administered IN, while arm tenderness was more common after IM administration. Significant increases in geometric mean serum antibody titers in both HAI and Nt assays were seen in all of the groups receiving influenza vaccine for all test antigens (P<or=.025, paired t-test), except for the B HAI antibody titer in the group that received 30mcg IN (P=.055, paired t-test). Postvaccination geometric mean serum antibody titers, the frequency of seroresponses, and the percentage achieving postvaccination serum HAI antibody titers of >or=32 were higher following delivery of the study vaccines by an IM route than by the IN route, but significant increases in serum antibody were seen after IN vaccination. Nasal IgA antibody responses were more common when vaccine was administered IN; and, when the IN dosage was increased, the primary benefit from IN vaccine over IM vaccine appeared to be greater induction of nasal secretory antibody.

Mesh:

Substances:

Year:  2007        PMID: 17559990      PMCID: PMC2063441          DOI: 10.1016/j.vaccine.2007.05.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine.

Authors:  Evgenia Greenbaum; Arthur Furst; Alexander Kiderman; Brendon Stewart; Reuven Levy; Miriam Schlesinger; Avraham Morag; Zichria Zakay-Rones
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

2.  Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.

Authors:  Evgenia Greenbaum; Dan Engelhard; Reuven Levy; Miriam Schlezinger; Avraham Morag; Zichria Zakay-Rones
Journal:  Vaccine       Date:  2004-06-30       Impact factor: 3.641

3.  Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

Authors:  John Treanor; Carrie Nolan; Diane O'Brien; David Burt; George Lowell; Janine Linden; Louis Fries
Journal:  Vaccine       Date:  2005-08-15       Impact factor: 3.641

4.  Immunization of elderly people with high doses of influenza vaccine.

Authors:  P A Gross; G V Quinnan; M E Weksler; P F Gaerlan; C R Denning
Journal:  J Am Geriatr Soc       Date:  1988-03       Impact factor: 5.562

5.  Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.

Authors:  W A Keitel; T R Cate; R L Atmar; C S Turner; D Nino; C M Dukes; H R Six; R B Couch
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

6.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus.

Authors:  M L Clements; R F Betts; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

7.  Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing-home residents by the use of high-dose vaccines.

Authors:  E J Remarque; W C van Beek; G J Ligthart; R J Borst; L Nagelkerken; A M Palache; M J Sprenger; N Masurel
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

8.  Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.

Authors:  Mordechai Muszkat; Evgenia Greenbaum; Arie Ben-Yehuda; Moses Oster; Efrain Yeu'l; Shmuel Heimann; Reuven Levy; Gideon Friedman; Zichria Zakay-Rones
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

9.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

Authors:  W A Keitel; R B Couch; T R Cate; K R Hess; B Baxter; J M Quarles; R L Atmar; H R Six
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

10.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.

Authors:  A L Frank; J Puck; B J Hughes; T R Cate
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

View more
  21 in total

1.  An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; Amber W McCall; Eng-Eong Ooi; Kanta Subbarao
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

3.  Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.

Authors:  Lisa A Jackson; Wilbur H Chen; Jack T Stapleton; Cornelia L Dekker; Anna Wald; Rebecca C Brady; Srilatha Edupuganti; Patricia Winokur; Mark J Mulligan; Harry L Keyserling; Karen L Kotloff; Nadine Rouphael; Diana L Noah; Heather Hill; Mark C Wolff
Journal:  J Infect Dis       Date:  2012-07-10       Impact factor: 5.226

4.  Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant.

Authors:  Tarek Hamouda; Joyce A Sutcliffe; Susan Ciotti; James R Baker
Journal:  Clin Vaccine Immunol       Date:  2011-05-04

5.  Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Authors:  Dorothy I Jones; Justin J Pollara; Brandi T Johnson-Weaver; Celia C LaBranche; David C Montefiori; David J Pickup; Sallie R Permar; Soman N Abraham; Massimo Maddaloni; David W Pascual; Herman F Staats
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

6.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

7.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

8.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.

Authors:  Rebecca Pellett Madan; Maria Tan; Ana Fernandez-Sesma; Thomas M Moran; Sukru Emre; Andrew Campbell; Betsy C Herold
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.